Fate Therapeutics Partners with Janssen for iPSC-derived Immunotherapies

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 5 (Table of Contents)

Published: 21 May-2020

DOI: 10.3833/pdr.v2020.i5.2539     ISSN: 1756-7874

Section: Research & Development



In a bid to bolster its immuno-oncology portfolio, Janssen Biotech has agreed to partner with Fate Therapeutics to develop induced pluripotent stem cell (iPSC)-derived product candidates for up to four tumour-associated antigen targets...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details